MAB Discovery GmbH based in Munich, was founded in 2010 and started operations in 2011 with experienced pharma scientists with a proven track record in drug development. MAB Discovery complies with the highest industrial standards of big pharma, but operates with the flexibility, speed and innovative spirit of a young biotech. The company’s outstanding technology platform offers its collaboration partners access to a large variety of fully functional drug candidates, and a unique route to CMC-compliant humanized mAb’s in 10-12 months.
Dr. Fischer spent 26 years in R&D at Boehringer-Mannheim/Roche Pharma Research where he focused on the discovery and development of biological based therapeutics.Stephan was a member of the team that developed erythropoietin (NeoRecormon®) and was the scientific and global project leader of the team that developed the thrombolytic reteplase (Retavase®, Rapilysin®) from discovery to launch. Stephan was a member of the global regulatory strategy committee for Biologics and the global task force for biosimilars. As Senior Vice President, Stephan led the Biologics research organization and developed the global strategy for Roche Biologicals with a focus on innovation and new technologies. Stephan received his PhD in Microbiology and conducted his post-doc at the European Molecular Biology Labs.
For over 26 years at Boehringer Mannheim / Roche, Dr. Krell was responsible for the development of high through put assays and screening of new diagnostic and biotechnological enzymes, natural compounds and low molecular weight compounds. More recently, Hans has focused on the discovery and characterization of novel therapeutic antibodies, employing innovative biochemical and cell based screens. In addition, Hans has been actively involved in global project management. Hans (co-) authored more than 40 patent applications and 60 publications. Hans holds a PhD from Freiburg University in biochemistry.